CPI-203 and IQS-01.01RS (CXCR4 inhibitor) co-treatment reduced tumor burden by downregulating MYC and p-AKT as well as enhancing apoptosis in DLBCL [97]. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.